Navigation Links
Neurologix Announces First Quarter 2011 Financial Results
Date:5/13/2011

arges of $0.8 million, or $0.03 per basic and diluted share, related to preferred stock dividends in connection with the Series D Stock and the Series C Stock.

The Company had cash and cash equivalents of approximately $5.4 million as of March 31, 2011.

Clark A. Johnson, President and Chief Executive Officer of Neurologix, noted that these first quarter financial results were consistent with the Company's expectations. "During the first quarter, our leadership in gene therapy was strongly confirmed by the publication in The Lancet Neurology of the positive results of our Phase 2 clinical trial of gene transfer for the treatment of advanced Parkinson's disease. These are the first successful Phase 2 gene therapy results in any therapeutic area that have been published in a peer-reviewed journal. As we have reported before, we are continuing on the path to develop NLX-P101, our Parkinson's disease gene transfer therapy, as a much needed therapy for patients with Parkinson's disease and plan to submit a Phase 3 protocol to the FDA later this year."

About NeurologixNeurologix, Inc. (OTCBB:NRGX) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system. Neurologix's therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. The Company's current programs address such conditions as Parkinson's disease, epilepsy, depression and Huntington's disease, all of which are large markets not adequately served by current therapeutic options. For more information, please visit the Neurologix website at http://www.neurologix.net.

Cautionary Statement Regarding Forward-Looking StatementsThis news release include
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. Neurologix Reports Third Quarter 2010 Financial Results
4. Neurologix Completes Additional $7 Million Financing
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Rock Creek Pharmaceuticals, ... it has initiated the development of its lead molecule, ... that it has selected Quotient Clinical, The Translational Pharmaceutics ... (UK) to run its early development programs. ... Application (CTA) by the end of the third quarter ...
(Date:7/31/2014)... 2014  A substantial share of pharmacy and ... therapies are included in formularies—say patient support resources ... new Manhattan Research study, Taking the Pulse® ... that P&T committee members in hospitals, managed care ... set a high bar for these programs, requiring ...
(Date:7/31/2014)... Portugal , July 31, 2014 ... Cork, Ireland has successfully passed a pre-approval inspection ... The inspection, carried out by the FDA Consumer Safety Officer, ... planned, started on 21 st July and concluded on ... be compliant with the principles and guidelines of Good Manufacturing ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2
... College of American Pathologists Outlines Recommendations at Food and Drug ... , ... increasing importance of laboratory tests in diagnosing and treating disease, representatives ... the Food and Drug Administration (FDA) urging increased oversight of laboratory ...
... CHICAGO and PASADENA, Calif. , July 20 ... that Huntington Memorial Hospital has selected the Allscripts ... Exchange (HIE) that enables physicians, hospitals and other health care providers ... team approach to patient care, regardless of where they are located ...
Cached Medicine Technology:CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 2CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 3CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 4Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 2Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 3Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 4Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 5Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 6Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 7
(Date:8/1/2014)... (PRWEB) August 01, 2014 Transparency ... announced the addition of a comprehensive report on ... ‘Infusion System Market (Large Volume, Disposable, Syringe, Ambulatory ... Growth, Trends And Forecast, 2013 – 2019’ is ... http://www.transparencymarketresearch.com . , To begin with, the ...
(Date:8/1/2014)... HealthDay Reporter , THURDAY, July 31, 2014 (HealthDay ... cafeteria fare, a new study suggests. The new research ... fourth graders brought from home met three of five National ... similar to results of other studies of children,s packed lunches ... foods and beverages are more common than fruits, vegetables and ...
(Date:8/1/2014)... older women with asthma often have worse health outcomes, they ... new study. "There is no doubt that women over ... concluded Dr. James Sublett, an allergist and president-elect of the ... organization news release. In fact, the asthma death rate ... times higher than in other groups of people, the study,s ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 For the ... their Organic Cotton Farm & Fiber Report and the ... for the entire organic cotton supply chain resulting in ... Pepper, the organization’s Managing Director, reports, “We are looking ... farmers are the beginning of a long value chain ...
(Date:8/1/2014)... August 01, 2014 Did you know that ... Sarcoma Awareness Month is to raise awareness across the country ... options for, sarcoma. According to the American Cancer Society, nearly ... 2014, while 12,000 new soft tissue sarcomas will be diagnosed. ... sarcoma tumors as they are other kinds of cancer,” said ...
Breaking Medicine News(10 mins):Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 3Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 2Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 3Health News:Older Women With Asthma Face Worse Health Outcomes 2Health News:Surveys Reveal the Top 10 Organic Cotton Users and the Top 10 Producing Countries 2Health News:July Was Sarcoma Awareness Month! 2Health News:July Was Sarcoma Awareness Month! 3Health News:July Was Sarcoma Awareness Month! 4
... Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a ... non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and ... provided a business update, and management reiterated its expectation ... completes the development and regulatory review of its lead ...
... ... ... is a critical piece of a healthy lifestyle, however, those who suffer from diabetes may ... of Sports Health: A Multidisciplinary Approach. Authors confirm that exercise can aid in diabetes treatment ...
... ... The Real Housewives of Orange County ,” Dr. Milind Ambe consulted with Lynne Curtin’s ... Orange County breast augmentation with the 19 year-old. , ... (Vocus) December 29, 2009 -- Newport Beach ...
... ... Texas, announced today that it has expanded its’ continuum of care with the addition of ... ... announced today that it has expanded its’ continuum of care to include Origins owned and ...
... , Department of Health Urges All Pennsylvanians ... federal Centers for Disease Control and Prevention, or CDC, has ... to Pennsylvania to date, the state Department of Health said ... certified providers, local health departments, and state health centers. ...
... have identified a role for enhanced activation of the ... either the TSC1 or the TSC2 protein. As indicated ... in an accompanying commentary, these data provide a rationale ... those with TSC-associated tumors. Tuberous sclerosis complex (TSC) ...
Cached Medicine News:Health News:Echo Therapeutics Provides Business Update 2Health News:Echo Therapeutics Provides Business Update 3Health News:Echo Therapeutics Provides Business Update 4Health News:Echo Therapeutics Provides Business Update 5Health News:Exercise May Reduce the Complications of Diabetes, According to Sports Health Journal Study 2Health News:Exercise May Reduce the Complications of Diabetes, According to Sports Health Journal Study 3Health News:Newport Beach Plastic Surgeon Educates About the Pros and Cons of Plastic Surgery 2Health News:Newport Beach Plastic Surgeon Educates About the Pros and Cons of Plastic Surgery 3Health News:Origins Recovery Centers Announces an Expansion of its Continuum of Care 2Health News:Origins Recovery Centers Announces an Expansion of its Continuum of Care 3
Micro-mini fiber optic light....
The MC-3 allows for simultaneous use of two lamps, with an additional built-in spare....
Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light....
Delivers one primary lamp and one backup lamp. The port accepts ACMI fiberoptic cables....
Medicine Products: